Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells

FEBS Letters

Volumn 580, Issue 25, 2006, Pages 5905-5909

  Real, Pedro J ^a   Sanz, Cristina ^a   Gutierrez, Olga ^a   Pipaon, Carlos ^a   Zubiaga, Ana M ^b   Fernandez Luna, Jose L ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Apoptosis; Bik; Chemotherapy; E2F

Indexed keywords

ANTIINFECTIVE AGENT; DOXORUBICIN; PROTEIN P53; TRANSCRIPTION FACTOR E2F2;

APOPTOSIS; ARTICLE; CANCER CELL; DRUG RESPONSE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CELL LINE, TUMOR; DNA, NEOPLASM; DOXORUBICIN; E2F TRANSCRIPTION FACTORS; HUMANS; MEMBRANE PROTEINS; NEOPLASMS; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; TRANS-ACTIVATION (GENETICS); TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750054426     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.08.088     Document Type: Article

References (21)

1. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., and Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8 (2001) 705-711
2. Ranger A.M., et al. Bad-deficient mice develop diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 100 (2003) 9324-9329
3. Tan T.T., et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7 (2005) 227-238
4. Qin J.Z., et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65 (2005) 6282-6293
5. Hershko T., and Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279 (2004) 8627-8634
6. Real P.J., et al. Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. Cancer Res. 65 (2005) 8151-8157
7. Muller H., et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 15 (2001) 267-285
8. Bell L.A., and Ryan K.M. Life and death decisions by E2F-1. Cell Death Differ. 11 (2004) 137-142
9. Bunz F., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
10. Real P.J., Sierra A., De Juan A., Segovia J.C., Lopez-Vega J.M., and Fernandez-Luna J.L. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21 (2002) 7611-7618
11. Shang Y., Hu X., DiRenzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
12. Krek W., Ewen M.E., Shirodkar S., Arany Z., Kaelin Jr. W.G., and Livingston D.M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78 (1994) 161-172
13. Holmberg C., Helin K., Sehested M., and Karlstrom O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 17 (1998) 143-155
14. Mathai J.P., Germain M., Marcellus R.C., and Shore G.C. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene 21 (2002) 2534-2544
15. Paquet C., Schmitt E., Beauchemin M., and Bertrand R. Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells. Apoptosis 9 (2004) 815-831
16. Kemp C.J., Sun S., and Gurley K.E. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 61 (2001) 327-332
17. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88 (1996) 1442-1455
18. Han J., Sabbatini P., and White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Mol. Cell Biol. 16 (1996) 5857-5864
19. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
20. Chen L., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17 (2005) 393-403
21. Willis S.N., and Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17 (2005) 617-625